Does uniQure N.V. (QURE) Stock have plenty of room for growth?

3d ago, source: bovnews

Goldman raised the price target for the uniQure N.V. (NASDAQ:QURE) stock from “a Buy” to “a Neutral”. The rating was released on February 29, 2024, according to finviz. We previously noted in another ...

Buy Rating Affirmed for uniQure Amid Strong Pipeline and Regulatory Progress

7d ago, source:

Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on uniQure (QURE – Research Report) and decreased the price target ...

UniQure: Q1 Earnings Snapshot

9d ago, source:

UniQure NV (QURE) on Tuesday reported a loss of $65.6 million in its first quarter. The Amsterdam-based company said it had a loss of $1.36 per share.

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

10d ago, source: Yahoo Finance

LEXINGTON, Mass. and AMSTERDAM, May 07, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical ...

UniQure: Q1 Earnings Snapshot

9d ago, source: The Washington Post

AMSTERDAM — AMSTERDAM — UniQure NV (QURE) on Tuesday reported a loss of $65.6 million in its first quarter. The Amsterdam-based company said it had a loss of $1.36 per share. The results ...

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

10d ago, source: Business Insider

and AMSTERDAM, May 07, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported ...